{"id":46118,"date":"2026-01-26T19:00:00","date_gmt":"2026-01-26T12:00:00","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=46118"},"modified":"2026-01-26T19:00:00","modified_gmt":"2026-01-26T12:00:00","slug":"divamics-showcases-lead-autoimmune-program-dvi-001-and-unveils-new-metabolic-program-dvi-004-at-jpm-week-2026","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=46118","title":{"rendered":"Divamics Showcases Lead Autoimmune Program DVI-001 and Unveils New Metabolic Program DVI-004 at JPM Week 2026"},"content":{"rendered":"

SAN FRANCISCO<\/span><\/span>, Jan. 26, 2026<\/span><\/span> \/PRNewswire\/ — Divamics (DIVAMICS), an AI-driven biotechnology company specializing in high-precision molecular discovery, highlighted the significant advancement of its internal pipeline during the\u00a0Biotech Showcase\u2122\u00a0at JPM Week 2026. The company provided updated milestones for its lead autoimmune program,\u00a0DVI-001, and announced the first disclosure of\u00a0DVI-004, a promising new metabolic disease program generated by its proprietary AI platform. The presentation centered on Divamics’ ability to bridge the gap between AI-driven prediction and clinical-ready assets.<\/p>\n

\n

\"Dr. <\/a>
Dr. John Zheng, Founder and CEO of Divamics, presents data from the partner program BGM1812 during Biotech Showcase\u2122 at JPM Week 2026<\/span><\/p>\n<\/div>\n

A Foundation in Molecular Excellence<\/span><\/b><\/p>\n

Founded <\/span>in 2021,\u00a0Divamics is led by a founding team with deep roots in the global computational chemistry community. CEO\u00a0Dr. John Zheng\u00a0and\u00a0Dr. Hao Liu\u00a0both earned their Ph.D.s from the University of Florida<\/span>, training within the prestigious\u00a0AMBER\u00a0molecular dynamics ecosystem.<\/p>\n

During his tenure in the U.S., Dr. Zheng pioneered the\u00a0MovableType\u00a0free energy algorithm, which secured a second-place global ranking in the SAMPL6 blind drug design challenge and earned commendation from Nobel Laureate\u00a0Roald Hoffmann. The technology’s industrial viability was further validated through its commercial integration by QuantumBio. This academic rigor is complemented by Dr. Liu’s extensive experience at Genentech, where she specialized in large-scale data architecture\u2014a critical pillar for Divamics’ AI-driven insights.<\/p>\n

The company’s scientific strategy is guided by\u00a0Dr. Kenneth M. Merz Jr.<\/span>, Chief Scientific Advisor and a world-renowned authority in computational chemistry, ensuring that Divamics remains at the forefront of molecular simulation technology.<\/p>\n

Market Validation and Strategic Global Footprint<\/span><\/b><\/p>\n

Divamics<\/span>‘ technological prowess is backed by strong commercial momentum. At the Showcase, the company highlighted its ongoing collaboration with BrightGene, which recently resulted in peer-reviewed research published in the\u00a0Journal of Medicinal Chemistry\u00a0(2025). The market’s interest in Divamics’ platform was further evidenced by more than 50 high-level partnering meetings <\/span>with global biopharma stakeholders during JPM Week.<\/p>\n

“JPM Week is the ideal stage to share our progress with the global life sciences community,” said\u00a0Dr. John Zheng<\/span>, Founder and CEO of Divamics. “By combining our U.S.-trained scientific expertise with China’s<\/span> robust and agile biotech infrastructure, we offer global partners a unique value proposition: high-precision molecular discovery delivered with exceptional capital efficiency and executional speed.”<\/p>\n

Divamics operates with a strategic global footprint, including its headquarters in\u00a0Suzhou, operational teams in\u00a0Shanghai and Beijing<\/span>, and a\u00a0Singapore hub\u00a0dedicated to fostering international R&D collaborations.<\/p>\n

About Divamics<\/span><\/b><\/p>\n

Divamics <\/span>is an AI-driven biotech company dedicated to bringing molecular precision to early-stage R&D. By integrating physics-based molecular dynamics with machine learning,\u00a0Divamics accelerates the transition from hit identification to preclinical candidate selection. The company offers both collaborative R&D services and a growing internal pipeline of partner-ready assets.<\/p>\n

Media Contact:<\/b>\u00a0Divamics, Marketing Department, marketing@divamics.com<\/a>\u00a0<\/span><\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n

SAN FRANCISCO<\/span><\/span>, Jan. 26, 2026<\/span><\/span> \/PRNewswire\/ — Divamics (DIVAMICS), an AI-driven biotechnology company specializing in high-precision molecular discovery, highlighted the significant advancement of its internal pipeline during the\u00a0Biotech Showcase\u2122\u00a0at JPM Week 2026. The company provided updated milestones for its lead autoimmune program,\u00a0DVI-001, and announced the first disclosure of\u00a0DVI-004, a promising new metabolic disease program generated by its proprietary AI platform. The presentation centered on Divamics’ ability to bridge the gap between AI-driven prediction and clinical-ready assets.<\/p>\n

\n

\"Dr. <\/a>
Dr. John Zheng, Founder and CEO of Divamics, presents data from the partner program BGM1812 during Biotech Showcase\u2122 at JPM Week 2026<\/span><\/p>\n<\/div>\n

A Foundation in Molecular Excellence<\/span><\/b><\/p>\n

Founded <\/span>in 2021,\u00a0Divamics is led by a founding team with deep roots in the global computational chemistry community. CEO\u00a0Dr. John Zheng\u00a0and\u00a0Dr. Hao Liu\u00a0both earned their Ph.D.s from the University of Florida<\/span>, training within the prestigious\u00a0AMBER\u00a0molecular dynamics ecosystem.<\/p>\n

During his tenure in the U.S., Dr. Zheng pioneered the\u00a0MovableType\u00a0free energy algorithm, which secured a second-place global ranking in the SAMPL6 blind drug design challenge and earned commendation from Nobel Laureate\u00a0Roald Hoffmann. The technology’s industrial viability was further validated through its commercial integration by QuantumBio. This academic rigor is complemented by Dr. Liu’s extensive experience at Genentech, where she specialized in large-scale data architecture\u2014a critical pillar for Divamics’ AI-driven insights.<\/p>\n

The company’s scientific strategy is guided by\u00a0Dr. Kenneth M. Merz Jr.<\/span>, Chief Scientific Advisor and a world-renowned authority in computational chemistry, ensuring that Divamics remains at the forefront of molecular simulation technology.<\/p>\n

Market Validation and Strategic Global Footprint<\/span><\/b><\/p>\n

Divamics<\/span>‘ technological prowess is backed by strong commercial momentum. At the Showcase, the company highlighted its ongoing collaboration with BrightGene, which recently resulted in peer-reviewed research published in the\u00a0Journal of Medicinal Chemistry\u00a0(2025). The market’s interest in Divamics’ platform was further evidenced by more than 50 high-level partnering meetings <\/span>with global biopharma stakeholders during JPM Week.<\/p>\n

“JPM Week is the ideal stage to share our progress with the global life sciences community,” said\u00a0Dr. John Zheng<\/span>, Founder and CEO of Divamics. “By combining our U.S.-trained scientific expertise with China’s<\/span> robust and agile biotech infrastructure, we offer global partners a unique value proposition: high-precision molecular discovery delivered with exceptional capital efficiency and executional speed.”<\/p>\n

Divamics operates with a strategic global footprint, including its headquarters in\u00a0Suzhou, operational teams in\u00a0Shanghai and Beijing<\/span>, and a\u00a0Singapore hub\u00a0dedicated to fostering international R&D collaborations.<\/p>\n

About Divamics<\/span><\/b><\/p>\n

Divamics <\/span>is an AI-driven biotech company dedicated to bringing molecular precision to early-stage R&D. By integrating physics-based molecular dynamics with machine learning,\u00a0Divamics accelerates the transition from hit identification to preclinical candidate selection. The company offers both collaborative R&D services and a growing internal pipeline of partner-ready assets.<\/p>\n

Media Contact:<\/b>\u00a0Divamics, Marketing Department, marketing@divamics.com<\/a>\u00a0<\/span><\/p>\n

<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[1],"tags":[],"class_list":["post-46118","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/46118","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=46118"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/46118\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=46118"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=46118"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=46118"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}